On May 8, 2023, Porton Pharma Solutions Ltd. (stock code: 300363) celebrated the grand opening of its Small Molecule Business Platform Headquarters, located in Minhang Economic and Technological Development Zone, Shanghai. This momentous event attracted nearly 200 representatives ranging from local government, customers, investors, and academia. Mr. Yujian Chen, Secretary of Shanghai Minhang District, Mr. Rui Li, Deputy Mayor of Shanghai Minhang District, Mr. Xiaoming Feng, Party Secretary/Executive Director of Shanghai Land Minhang (Group) Co., Ltd, and Mr. Nianfeng (Oliver) Ju, Chairman and CEO of Porton, attended this ceremony.
The newly established headquarters and R&D center is located in No. 188 Beidou Road, Minhang District, Shanghai, which covers an area of more than 26 acres with two independent buildings. With an expansive 22,000 square meters of coverage, the facility hosts cutting-edge laboratories and synthesis facilities for a range of molecules.
Porton is also taking advantage of a large breadth of innovative technologies and capabilities at this site, including Bio-technology, Metal Catalysis, Flow Chemistry, Photo- and Electro- Chemistry, Crystallization, Milling and more. In addition, Porton has set up a new Synthetic Macromolecular Services Department here, covering an area of more than 3,000 square meters and equipped with state-of-the-art international standard laboratories, which will provide peptide drugs, oligonucleotide drugs, conjugate drugs, and other services for global pharmaceutical companies and new drug research organizations.
The Chairman and CEO of Porton, Mr. Ju Nianfeng, emphasized in his speech the company’s unwavering commitment to its core principles, highlighting a customer-first mindset, a commitment to top talent, continual technological investment, and management innovation as the backbone of Porton’s success.
At the opening ceremony, Porton Green Chemistry Research and Development Center was officially unveiled, marking another significant milestone in the company’s development of green chemistry. Starting from R&D, Porton follows the principles of green drug development, optimizing process parameters and control methods, actively developing and applying environmentally-friendly technologies such as biocatalysis, metal catalysis, flow chem, photo-electro chem and etc. to improve product yield, reducing waste generation and emissions, and recovering solvents and heavy metals. In the future, Porton Green Chemistry Research and Development Center will continue to utilize green chemistry and achieve high-quality and sustainable development for the industry.
With the establishment of the Small Molecule Platform Headquarters, Porton now boasts seven R&D and production facilities in Shanghai, covering end-to-end and full-category CDMO services such as drug substance, drug preparation, synthetic macromolecules and biological macromolecules (under construction).
About Porton
Founded in 2005, Porton Pharma Solutions Ltd.is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for small molecule, large molecule and gene and cell therapies from pre-clinical to commercialization. With more than 5000 skilled employees working across more than 20 sites around the globe, Porton is committed to becoming the most open, innovative and reliable pharmaceutical service platform in the world and enabling the public’s early access to good medicines. As the end of 2022, we have established business contacts with nearly 800 customers worldwide and has over 2,200 successful project delivery experiences.